CELG

Celgene Corp

Healthcare


Presented:04/18/2018
Price:$91.01
Cap:$70.40B
Current Price:$108.24
Cap:$77.04B

Presented

Date04/18/2018
Price$91.01
Market Cap$70.40B
Ent Value$84.50B
P/E Ratio25.42x
Book Value$9.12
Div Yield0%
Shares O/S773.50M
Ave Daily Vol7,681,903
Short Int1.58%

Current

Price$108.24
Market Cap$77.04B
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Publicly traded companies mentioned herein: Amgen Inc (AMGN), Biogen Inc (BIIB), Bristol-Myers Squibb Co (BMY), Celgene Corp (CELG), Gilead Sciences Inc (GILD), Pfizer Inc (PFE), Novartis AG (NVS), Shire plc (SHPG)

Highlights

The presenter is long shares of Celgene (CELG), seeing attractive upside from what he perceives to be an unreasonably depressed valuation. CELG still leads peers in its oncology platform and is set to generate significant amounts of cash flow over the next 3 - 4 years, which could help improve investor sentiment around company management.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.